BridgeBio Pharma [BBIO] vs Regeneron [REGN] Detailed Stock Comparison

BridgeBio Pharma Inc.

NASDAQ
Loading...

Regeneron Pharmaceuticals, Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: BridgeBio Pharma Inc. wins in 4 metrics, Regeneron Pharmaceuticals, Inc. wins in 15 metrics, with 0 ties. Regeneron Pharmaceuticals, Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric BridgeBio Pharma Inc. Regeneron Pharmaceuticals, Inc. Better
P/E Ratio (TTM) -19.38 18.00 Regeneron Pharmaceuticals, Inc.
Price-to-Book Ratio -6.83 2.45 Regeneron Pharmaceuticals, Inc.
Debt-to-Equity Ratio -0.90 9.51 Regeneron Pharmaceuticals, Inc.
PEG Ratio 0.68 -4.80 BridgeBio Pharma Inc.
EV/EBITDA -30.56 16.72 Regeneron Pharmaceuticals, Inc.
Profit Margin (TTM) -144.39% 31.41% Regeneron Pharmaceuticals, Inc.
Operating Margin (TTM) -83.30% 23.13% Regeneron Pharmaceuticals, Inc.
EBITDA Margin (TTM) N/A 23.13% N/A
Return on Equity 34.91% 14.86% BridgeBio Pharma Inc.
Return on Assets (TTM) -33.83% 5.91% Regeneron Pharmaceuticals, Inc.
Free Cash Flow (TTM) $-455.50M $3.77B Regeneron Pharmaceuticals, Inc.
Dividend Yield N/A 0.59% N/A
1-Year Return 93.46% 25.39% BridgeBio Pharma Inc.
Price-to-Sales Ratio (TTM) 28.30 5.50 Regeneron Pharmaceuticals, Inc.
Enterprise Value $15.18B $70.98B Regeneron Pharmaceuticals, Inc.
EV/Revenue Ratio 30.23 4.95 Regeneron Pharmaceuticals, Inc.
Gross Profit Margin (TTM) 94.74% 84.95% BridgeBio Pharma Inc.
Revenue per Share (TTM) $3 $137 Regeneron Pharmaceuticals, Inc.
Earnings per Share (Diluted) $-3.87 $41.48 Regeneron Pharmaceuticals, Inc.
Beta (Stock Volatility) 1.09 0.40 Regeneron Pharmaceuticals, Inc.
Short % of Float 20.04% 2.55% Regeneron Pharmaceuticals, Inc.

BridgeBio Pharma Inc. vs Regeneron Pharmaceuticals, Inc. Stock Performance Analysis

Loading Price Chart...

BBIO
REGN

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
BridgeBio Pharma Inc.2.50%-5.68%-7.41%-2.47%-10.61%-18.35%
Regeneron Pharmaceuticals, Inc.2.66%-5.03%-15.02%-23.79%-18.77%-22.36%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
BridgeBio Pharma Inc.93.46%364.66%14.32%145.68%145.68%145.68%
Regeneron Pharmaceuticals, Inc.25.39%-16.92%20.10%53.41%959.24%4,557.42%

Performance & Financial Health Analysis: BridgeBio Pharma Inc. vs Regeneron Pharmaceuticals, Inc.

MetricBBIOREGN
Market Information
Market Cap i$14.21B$80.98B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i2,063,126642,495
90 Day Avg. Volume i1,729,435617,765
Last Close$65.48$618.95
52 Week Range$35.15 - $84.94$476.49 - $821.11
% from 52W High-22.91%-24.62%
All-Time High$84.94 (Feb 12, 2026)$1,211.20 (Aug 26, 2024)
% from All-Time High-22.91%-48.90%
Growth Metrics
Quarterly Revenue Growth25.21%0.03%
Quarterly Earnings Growth25.21%-0.08%
Financial Health
Profit Margin (TTM) i-1.44%0.31%
Operating Margin (TTM) i-0.83%0.23%
Return on Equity (TTM) i0.35%0.15%
Debt to Equity (MRQ) i-0.909.51
Cash & Liquidity
Book Value per Share (MRQ)$-10.71$304.65
Cash per Share (MRQ)$3.03$83.86
Operating Cash Flow (TTM) i$-445,910,016$4.98B
Levered Free Cash Flow (TTM) i$-325,290,624$3.26B
Dividends
Last 12-Month Dividend Yield iN/A0.59%
Last 12-Month Dividend iN/A$4.46

Valuation & Enterprise Metrics Analysis: BridgeBio Pharma Inc. vs Regeneron Pharmaceuticals, Inc.

MetricBBIO (Apr 26, 2026)REGN (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-19.3818.00
Forward P/E i355.7314.21
PEG Ratio i0.68-4.80
Price to Sales (TTM) i28.305.50
Price to Book (MRQ) i-6.832.45
Market Capitalization
Market Capitalization i$14.21B$80.98B
Enterprise Value i$15.18B$70.98B
Enterprise Value Metrics
Enterprise to Revenue i30.234.95
Enterprise to EBITDA i-30.5616.72
Risk & Other Metrics
Beta i1.090.40
Book Value per Share (MRQ) i$-10.71$304.65

Financial Statements Comparison: BridgeBio Pharma Inc. vs Regeneron Pharmaceuticals, Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBBIO (2025)REGN (2025)
Revenue/Sales i502.08M14.34B
Cost of Goods Sold i20.96M2.10B
COGS % of Revenue i4.2%14.6%
Gross Profit i481.11M12.24B
Gross Margin i95.8%85.4%
Research & Development i451.95M5.85B
Operating Income (EBIT) i-502.06M3.70B
Operating Margin i-100.0%25.8%
EBITDA i-506.33M5.00B
EBITDA Margin i-100.8%34.8%
Pre-Tax Income i-732.50M5.23B
Pre-Tax Income % of Revenue i-145.9%36.5%
Income Tax i435,000725.80M
Income Tax % of Revenue i0.1%5.1%
Net Income (Profit) i-732.94M4.50B
Profit Margin i-146.0%31.4%

Balance Sheet & Liquidity Metrics

MetricBBIO (2025)REGN (2025)
Cash & Equivalents i570.12M3.12B
Total Current Assets i797.75M18.02B
Total Current Assets % of Revenue i158.9%125.7%
Total Current Liabilities i287.97M4.37B
Total Current Liabilities % of Revenue i57.4%30.5%
Long-Term Debt i1.86B2.71B
Long-Term Debt % of Revenue i369.7%18.9%
Total Shareholders Equity i-2.08B31.26B
Retained Earnings i-3.82B35.80B
Retained Earnings % of Revenue i-761.1%249.6%
Property, Plant & Equipment i13.52M1.54B

Cash Flow Statement Comparison

MetricBBIO (2025)REGN (2025)
Operating Cash Flow i-530.95M6.30B
Operating Cash Flow % of Revenue i-105.7%43.9%
Capital Expenditures i-1.10M0
Free Cash Flow i-455.50M3.77B
FCF Margin i-90.7%26.3%
Debt Repayment i-459.00MN/A
Common Stock Repurchase i-62.50M-3.97B

Short Interest & Institutional Ownership Analysis

MetricBBIOREGN
Shares Short i23.37M2.55M
Short Ratio i11.214.46
Short % of Float i20.04%2.55%
Shares Outstanding i194.77M105.72M
Float Shares i160.80M98.55M
% Held by Insiders i4.28%1.98%
% Held by Institutions i100.73%91.08%
% Held by Public i-5.01%6.94%

Dividend Analysis & Yield Comparison: BridgeBio Pharma Inc. vs Regeneron Pharmaceuticals, Inc.

MetricBBIOREGN
Last 12-Month Dividend iN/A$4.46
Last 12-Month Dividend Yield iN/A0.59%
3-Year Avg Annual Dividend iN/A$1.49
3-Year Avg Dividend Yield iN/A0.13%
3-Year Total Dividends iN/A$4.46
Ex-Dividend DateN/AFeb 20, 2026